Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells.

NCT ID: NCT02852954

Last Updated: 2017-08-18

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-08-31
• Study Completion Date: 2017-03-31

Brief Summary

Immune system suppression effect of Progesterone Induced Blocking Factor(PIBF), it could be questionable whether tumor cells express PIBF for escape of immune system. There are some studies in the literature that evaluate PIBF expression of different malign cells (e.g. glioblastoma multiforme as a malign central nerve system, leukemia, astrocytoma as a primary brain tumor, lung cancer and chorionic carcinoma). According to previous studies PIBF has been used as an anti-tumor immune suppressor by tumor cells. There is no data about the PIBF expression of endometrial tumor cells. Therefore, the investigators aim to determine the PIBF expression levels in the endometrial cancer cells.

Detailed Description

This retrospective controlled study will be conducted at both Obstetrics and Gynecology clinics and Pathology clinics of Kayseri Training and Research Hospital. This study will be conducted with the use of formalin fixed paraffin embedded tissue blocks immunohistochemically to determine the PIBF expression levels in the samples. There are three groups in this study; endometrial cancer, endometrial hyperplasia and normal endometrium and each of the groups contained 20 paraffin embedded blocks provided form the Pathology clinic of Kayseri Training and Research Hospital archives.

Conditions

Progesterone Induced Blocking Factor in Endometrial Cancer

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: RETROSPECTIVE

Study Groups

study group1

20 paraffin embedded blocks which was diagnosed endometrial cancer

No interventions assigned to this group

control group

20 paraffin embedded blocks of healthy women

No interventions assigned to this group

study group2

20 paraffin embedded blocks which was diagnosed endometrial hyperplasia

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• diagnosed endometrial cancer
• diagnosed endometrial hyperplasia

Exclusion Criteria

• diagnosed cancer except endometrial cancer

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Kayseri Education and Research Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Erdem Sahin

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

2016/405

Identifier Type: -

Identifier Source: org_study_id